

Trends and Determinants of Tramadol Consumption in Chile: Evidence from National Health Surveys (2003–2017)

Table 1. Characteristics of participants in the three National Surveys (ENS) (Non-weighted sample)

	2003						2010						2017					
N	All		Hombres		Mujeres		All		Hombres		Mujeres		All		Hombres		Mujeres	
	3448		1568		1880		4760		1900		2860		5379		1950		3429	
Age (mean, sd)	41.1 (0.4)		40.2 (0.5)		42.0 (0.5)		42.6 (0.5)		41.7 (0.6)		43.3 (0.6)		44.5 (0.4)		43.8 (0.7)		45.2 (0.5)	
	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Age group																		
17-24	395	11.5%	199	12.7%	196	10.4%	603	12.7%	253	13.3%	350	12.2%	588	10.9%	247	12.7%	341	9.9%
25-44	1062	30.8%	510	32.5%	552	29.4%	1613	33.9%	636	33.5%	977	34.2%	1571	29.2%	557	28.6%	1014	29.6%
45-64	1105	32.0%	483	30.8%	622	33.1%	1611	33.8%	649	34.2%	962	33.6%	1857	34.5%	658	33.7%	1199	35.0%
65+	886	25.7%	376	24.0%	510	27.1%	933	19.6%	362	19.1%	571	20.0%	1363	25.3%	488	25.0%	875	25.5%
Educational level																		
Low	1778	51.6%	768	49.0%	1010	53.7%	1289	27.1%	475	25.0%	814	28.5%	1325	24.6%	413	21.2%	912	26.6%
Medium	1236	35.8%	564	36.0%	672	35.7%	2543	53.4%	1045	55.0%	1498	52.4%	2811	52.3%	1038	53.2%	1773	51.7%
High	426	12.4%	232	14.8%	194	10.3%	911	19.1%	375	19.7%	536	18.7%	1196	22.2%	483	24.8%	713	20.8%
Zone																		
Rural	622	18.0%	322	20.5%	300	16.0%	711	14.9%	273	14.4%	438	15.3%	859	16.0%	281	14.4%	578	16.9%
Cancer	35	1.0%	2	0.1%	33	1.8%	30	0.6%	1	0.1%	29	1.0%	253	4.7%	54	2.8%	199	5.8%
Osteoarthritis	183	5.3%	42	2.7%	141	7.5%	304	6.4%	68	3.6%	236	8.3%	585	10.9%	106	5.4%	479	14.0%
Depression	562	16.3%	156	9.9%	406	21.6%	664	13.9%	134	7.1%	530	18.5%	631	11.7%	147	7.5%	484	14.1%
MS1	1483	43.0%	540	34.4%	943	50.2%	1977	41.5%	616	32.4%	1361	47.6%	1570	29.2%	423	21.7%	1147	33.4%
MS2	1335	38.7%	480	30.6%	855	45.5%	1816	38.2%	542	28.5%	1274	44.5%	1449	26.9%	372	19.1%	1077	31.4%

Table 2. Logistic regression models for Tramadol consumption, adjusted for age and sex, for each clinical condition.

	OR	conf.low	conf.high	std.error	statistic	p.value
MS1 (n=10258)						
(Intercept)	0	0	0	0.62	-14.18	0
Age	1.05	1.04	1.06	0	10.29	0
Sex Female	1.82	0.82	4.03	0.41	1.47	0.14
ENS 2017	5.31	1.85	15.22	0.54	3.11	0
MS1	2.7	0.8	9.1	0.62	1.6	0.11
ENS 2017:MS1	0.59	0.14	2.49	0.73	-0.71	0.48
MS2 (n=10254)						
(Intercept)	0	0	0	0.62	-14.21	0
Age	1.05	1.04	1.06	0	10.16	0
Sex Female	1.78	0.79	3.98	0.41	1.4	0.16
ENS 2017	5.45	1.92	15.52	0.53	3.18	0
MS2	3.09	0.92	10.41	0.62	1.82	0.07
ENS 2017:MS2	0.57	0.14	2.38	0.72	-0.77	0.44
Osteoarthritis (n=10361)						
(Intercept)	0	0	0	0.56	-13.14	0
Age	1.03	1.02	1.05	0.01	4.01	0
Sex Female	1.33	0.67	2.64	0.35	0.81	0.42
ENS 2017	2.27	0.9	5.71	0.47	1.75	0.08
Osteoarthritis	10.25	2.74	38.37	0.67	3.46	0
ENS 2017:Osteoarthritis	1.14	0.23	5.56	0.81	0.16	0.87
Depression (n=10389)						
(Intercept)	0	0	0	0.56	-16.66	0
Age	1.06	1.05	1.07	0.01	10.33	0
Sex Female	1.65	0.74	3.67	0.41	1.22	0.22
ENS 2017	4.85	2.08	11.33	0.43	3.65	0
Depression	9.62	2.63	35.16	0.66	3.43	0
ENS 2017:Depression	0.37	0.08	1.76	0.8	-1.25	0.21
Cancer (n=10294)						
(Intercept)	0	0	0	0.46	-18.48	0
Age	1.06	1.04	1.07	0.01	9.51	0
Sex Female	2.34	1.08	5.05	0.39	2.17	0.03
ENS 2017	3.02	1.41	6.47	0.39	2.85	0
Cancer	2.58	0.4	16.53	0.95	1	0.32
ENS 2017:cancer	0.52	0.06	4.36	1.08	-0.6	0.55